Vegetative Clostridium difficile survives in room air on moist surfaces and in gastric contents with reduced acidity: A potential mechanism to explain the association between proton pump inhibitors and C. difficile-associated diarrhea?

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 8, 2007, Pages 2883-2887

  Jump, Robin L P ^b   Pultz, Michael J ^a   Donskey, Curtis J ^a,c  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^c LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTON PUMP INHIBITOR;

ACIDITY; AMBIENT AIR; ARTICLE; BACTERIAL SPORE; BACTERIAL SURVIVAL; CLOSTRIDIUM DIFFICILE; CONTROLLED STUDY; DIARRHEA; DRUG INDUCED DISEASE; INFECTION RISK; INFECTION SENSITIVITY; MOISTURE; NONHUMAN; PRIORITY JOURNAL; STOMACH CONTENT;

AEROBIOSIS; ANAEROBIOSIS; ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; CLOSTRIDIUM DIFFICILE; COLONY COUNT, MICROBIAL; DIARRHEA; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FECES; GASTROINTESTINAL CONTENTS; HUMANS; HYDROGEN-ION CONCENTRATION; PROTON PUMPS; SPORES, BACTERIAL; WATER;

EID: 34547635096     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01443-06     Document Type: Article

References (32)

1. Al-Tureihi, F. I., A. Hassoun, G. Wolf-Klein, and H. Isenberg. 2005. Albumin, length of stay, and proton pump inhibitors: key factors in Clostridium difficile-associated disease in nursing home patients. J. Am. Med. Dir. Assoc. 6:105-108.
2. Buggy, B. P., K. H. Wilson, and R. Fekety. 1983. Comparison of methods for recovery of Clostridium difficile from an environmental surface. J. Clin. Microbiol. 18:348-352.
3. Cunningham, R., B. Dale, B. Undy, and N. Gaunt. 2003. Proton pump inhibitors as a risk factor for Clostridium difficile diarrhoea. J. Hosp. Infect. 54:243.
4. Dial, S., J. A. Delaney, V. Schneider, and S. Suissa. 2006. Proton pump inhibitor use and risk of community-acquired Clostridium difficile-associated disease defined by prescription for oral vancomycin therapy. Can. Med. Assoc. J. 175:745-748.
5. Dial, S., J. A. C. Delaney, A. N. Barkun, and S. Suissa. 2005. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 294:2989-2995.
6. Freeman, J., and M. H. Wilcox. 2003. The effects of storage conditions on viability of Clostridium difficile vegetative cells and spores and toxin activity in human faeces. J. Clin. Pathol. 56:126-128.
7. George, W. L., V. L. Sutter, D. Citron, and S. M. Finegold. 1979. Selective and differential medium for isolation of Clostridium difficile. J. Clin. Microbiol. 9:214-219.
8. Gurian, L., T. T. Ward, and R. M. Raton. 1982. Possible foodborne transmission in a case of pseudomembranous colitis due to Clostridium difficile: influence of gastrointestinal secretions on Clostridium difficile infection. Gastroenterology 83:465-469.
9. Johnson, S., M. H. Samore, K. A. Farrow, G. E. Killgore, F. C. Tenover, D. Lyras, J. I. Rood, P. DeGirolami, A. L. Baltch, M. E. Rafferty, S. M. Pear, and D. N. Gerding. 1999. Epidemics of diarrhea caused by a clindamycin-resistant strain of Clostridium difficile in four hospitals. N. Engl. J. Med. 341:1645-1651.
10. Karmeli, Y., R. Stalnikowitz, R. Eliakim, and G. Rahav. 1995. Conventional dose of omeprazole alters gastric flora. Dig. Dis. Sci. 40:2070-2073.
11. Kim, K. H., R. Fekety, D. H. Batts, D. Brown, M. Cudmore, J. Silva, Jr., and D. Waters. 1981. Isolation of Clostridium difficile from the environment and contacts of patients with antibiotic-associated colitis. J. Infect. Dis. 143:42-50.
12. Kyne, L., M. B. Hamel, R. Polavaram, and C. P. Kelly. 2002. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin. Infect. Dis. 34:346-353.
13. Kyne, L., S. Sougioultzis, L. V. McFarland, and C. P. Kelly. 2002. Underlying disease severity as a major risk factor for nosocomial Clostridium difficile diarrhea. Infect. Control Hosp. Epidemiol. 23:653-659.
14. Loo, V. G., L. Poirier, M. A. Miller, M. Oughton, M. D. Libman, S. Michaud, A. M. Bourgault, T. Nguyen, C. Frenette, M. Kelly, A. Vibien, P. Brassard, S. Fenn, K. Dewar, T. J. Hudson, R. Horn, P. Rene, Y. Monczak, and A. Dascal. 2005. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N. Engl. J. Med. 353:2442-2449.
15. Lowe, D. O., M. M. Mamdani, A. Kopp, D. E. Low, and D. N. Juurlink. 2006. Proton pump inhibitors and hospitalization for Clostridium difficile-associated disease: a population-based study. Clin. Infect. Dis. 43:1272-1276.
16. McDonald, L. C., G. E. Killgore, A. Thompson, R. C. Owens, Jr., S. V. Kazakova, S. P. Sambol, S. Johnson, and D. N. Gerding. 2005. An epidemic, toxin gene-variant strain of Clostridium difficile. N. Engl. J. Med. 353:2433-2441.
17. McDonald, L. C., M. Owings, and D. B. Jernigan. 2006. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg. Infect. Dis. 12:409-415.
18. Merrigan, M. M., S. P. Sambol, S. Johnson, and D. N. Gerding. 2003. Prevention of fatal Clostridium difficile-associated disease during continuous administration of clindamycin in hamsters. J. Infect. Dis. 188:1922-1927.
19. Nehra, D., P. Howell, C. P. Williams, J. K. Pye, and J. Beynon. 1999. Toxic bile acids in gastro-oesophageal reflux disease: influence of gastric acidity. Gut 44:598-602.
20. Pepin, J., N. Saheb, M. A. Coulombe, M. E. Alary, M. P. Corriveau, S. Authier, M. Leblanc, G. Rivard, M. Bettez, V. Primeau, M. Nguyen, C. E. Jacob, and L. Lanthier. 2005. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin. Infect. Dis. 41:1254-1260.
21. Rao, A., R. L. Jump, N. J. Pultz, M. J. Pultz, and C. J. Donskey. 2006. In vitro killing of nosocomial pathogens by acid and acidified nitrite. Antimicrob. Agents Chemother. 50:3901-3904.
22. Shah, S., A. Lewis, D. Leopold, F. Dunstan, and K. Woodhouse. 2000. Gastric acid suppression does not promote clostridial diarrhoea in the elderly. Q. J. Med. 93:175-181.
23. Sharma, B. K., I. A. Santana, E. C. Wood, R. P. Walt, M. Pereira, P. Noone, P. L. Smith, C. L. Walters, and R. E. Pounder. 1984. Intragastric bacterial activity and nitrosation before, during, and after treatment with omeprazole. Br. Med. J. Clin. Res. 289:717-719.
24. Sonnenberg, A. 1994. Esophogeal disease, p. 299-355. In J. E. Everhart (ed.), Digestive diseases in the United States: epidemiology and impact - NIH publication no. 94-1447. National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Washington, DC.
25. Thorens, J., F. Froehlich, W. Schwizer, E. Saraga, J. Bille, K. Gyr, P. Duroux, M. Nicolet, B. Pignatelli, A. L. Blum, J. J. Gonvers, and M. Fried. 1996. Bacterial overgrowth during treatment with omeprazole compared with cimetidine: a prospective randomised double blind study. Gut 39:54-59.
26. Verdu, E., F. Viani, D. Armstrong, R. Fraser, H. H. Siegrist, B. Pignatelli, J. P. Idstrom, C. Cederberg, A. L. Blum, and M. Fried. 1994. Effect of omeprazole on intragastric bacterial counts, nitrates, nitrites, and N-nitroso compounds. Gut 35:455-460.
27. Weese, J. S., H. R. Staempfli, and J. F. Prescott. 2000. Survival of Clostridium difficile and its toxins in equine feces: implications for diagnostic test selection and interpretation. J. Vet. Diagn. Investig. 12:332-336.
28. Wilcox, M. H., W. N. Fawley, and P. Parnell. 2000. Value of lysozyme agar incorporation and alkaline thioglycollate exposure for the environmental recovery of Clostridium difficile. J. Hosp. Infect. 44:65-69.
29. Willey, S. H., and J. G. Bartlett. 1979. Cultures for Clostridium difficile in stools containing a cytotoxin neutralized by Clostridium sordellii antitoxin. J. Clin. Microbiol. 10:880-884.
30. Wilson, K. H. 1983. Efficiency of various bile salt preparations for stimulation of Clostridium difficile spore germination. I. Clin. Microbiol. 18:1017-1019.
31. Wilson, K. H., J. N. Sheagren, and R. Freter. 1985. Population dynamics of ingested Clostridium difficile in the gastrointestinal tract of the Syrian hamster. J. Infect. Dis. 151:355-361.
32. Yearsley, K. A., L. J. Gilby, A. V. Ramadas, E. M. Kubiak, D. L. Fone, and M. C. Allison. 2006. Proton pump inhibitor therapy is a risk factor for Clostridium difficile-associated diarrhoea. Aliment. Pharmacol. Ther. 24:613-619.